BRIEF-Bridgebio Announces FDA Acceptance And Priority Review Of NDA For Oral Infigratinib For Children With Achondroplasia

Reuters2026/10/06 11:50

BridgeBio Pharma, Inc. BBIO.O: BRIDGEBIO ANNOUNCES FDA ACCEPTANCE AND PRIORITY REVIEW OF NDA FOR ORAL INFIGRATINIB FOR CHILDREN WITH ACHONDROPLASIA BRIDGEBIO PHARMA - FDA SETS PDUFA TARGET ACTION DATE OF FEBRUARY 4, 2027 FOR ORAL INFIGRATINIB BRIDGEBIO PHARMA - ANTICIPATES U.S. LAUNCH OF ORAL INFIGRATINIB UPON APPROVAL BRIDGEBIO PHARMA - TO SUBMIT MAA FOR ACHONDROPLASIA TO EMA IN Q4 2026 Source text: ID:nGNX6F4nsd Further company coverage: BBIO.O

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.